State Mushroom Psychedelic Research

The State of Mushroom & Psychedelic Research: June 2026

ByRowan Hale

The State of Mushroom & Psychedelic Research: June 2026

The big picture. ShroomWire is tracking 1531 studies across mushrooms, psychedelics, and brain-health research, each graded A–F for evidence strength. Here’s where the evidence actually stands this month — including how much is still early-stage, and what’s been retracted.

Evidence strength across everything we track

Most of the field is still early — and we think saying so plainly is the point.

Grade A58 (4%)
Grade B70 (5%)
Grade C565 (37%)
Grade D657 (43%)
Grade E15 (1%)
Grade F166 (11%)

What’s being researched

Psychedelics523 (34%)
Functional mushrooms466 (30%)
Neuroscience271 (18%)
Mycology & materials271 (18%)

Early-signal & integrity watch

  • 239 tracked items are preprints (not yet peer-reviewed) — promising but provisional.
  • 0 are flagged retracted and are never presented as standing evidence.

Most notable studies right now

Methodology: see how we grade the evidence. This is a living snapshot, regenerated regularly from our research database.

## Educational Disclaimer

This article is for informational and educational purposes only. It is not
medical advice, mental health advice, diagnosis, treatment guidance, or a
recommendation to use any substance, supplement, therapy, or protocol.

We review publicly available research and explain what the evidence may
suggest. Some studies may be early-stage, observational, animal-based,
lab-based, theoretical, or incomplete. Always consult a qualified
professional before making health-related decisions.

Frequently asked questions

Is the current research on psychedelics and mushrooms reliable?
Most of the field is still early-stage, with 43% of studies graded as D and 11% graded as F, indicating that the evidence is not yet strong. However, some studies have been graded as A or B, suggesting that they have stronger evidence.
What are the potential therapeutic uses of psilocybin being researched?
Researchers are exploring the potential of psilocybin-assisted therapy for treatment-resistant depression, borderline personality disorder, and schizophrenia spectrum disorder, among other conditions. However, it's essential to note that this is not medical advice, and the evidence is still emerging.
Are there any safety concerns associated with psilocybin research?
The article does not report any retracted studies or major safety concerns. However, it's crucial to consult a qualified professional before making any health-related decisions, as the research is ongoing and not all studies have been peer-reviewed.

Similar Posts